Candid Therapeutics launched Monday with $370 million in funding. Its goal is to manufacture bispecific T-cell engagers (TCEs) to combat autoimmune disorders. The company has not only raised a huge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results